Wave Life Sciences price target raised to $19 from $10 at Mizuho

Mizuho raised the firm’s price target on Wave Life Sciences to $19 from $10 and keeps a Buy rating on the shares. The analyst increased its unadjusted peak sales for Inhbe to $2.5B from $1.5B, saying the company is moving quickly on the asset and GSK is now the number two holder of this stock. The firm says not much is priced into the shares “for really any asset.” If any of Wave’s programs begin to work, “it’s not too hard to see the stock head into the teens / low’s $20’s,” the analyst tells investors in a research note.